5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F20%3A00536981" target="_blank" >RIV/68378041:_____/20:00536981 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/20:10402394 RIV/00216208:11120/20:43919369 RIV/00216208:11140/20:10402394 RIV/00064190:_____/20:N0000087

Result on the web

<a href="https://www.sciencedirect.com/science/article/abs/pii/S0163725819301998?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S0163725819301998?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.pharmthera.2019.107447" target="_blank" >10.1016/j.pharmthera.2019.107447</a>

Result language

angličtina

Original language name

5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future

Original language description

5-Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal cancer (CRC) in the palliative and adjuvant settings. Over the past four decades, several modulation strategies including the implementation of 5-FU-based combination regimens and 5-FU pro-drugs have been developed and tested to increase the anti-tumor activity of 5-FU and to overcome the clinical resistance.nDespite the encouraging progress in CRC therapy to date, the patients response rates to therapy continue to remain low and the patients benefit from 5-FU-based therapy is frequently compromised by the development of chemoresistance. Inter-individual differences in the treatment response in CRC patients may originate in the unique genetic and epigenetic make-up of each individual.nThe critical element in the current trend of personalized medicine is the proper comprehension of causes and mechanisms contributing to the low or lack of sensitivity of tumor tissue to 5-FU-based therapy. The identification and validation of predictive biomarkers for existing 5-FU-based and new targeted therapies for CRC treatment will likely improve patients' outcomes in the future.nHerein we present a comprehensive review summarizing options of CRC treatment and the mechanisms of 5-FU action at the molecular level, including both anabolic' and catabolic ways. The main part of this review comprises the currently known molecular mechanisms underlying the chemoresistance in CRC patients. We also focus on various 5-FU pro-drugs developed to increase the amount of circulating 5-FU and to limit toxicity. Finally, we propose future directions of personalized CRC therapy according to the latest published evidence.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Pharmacology and Therapeutics

ISSN

0163-7258

e-ISSN

—

Volume of the periodical

206

Issue of the periodical within the volume

feb.

Country of publishing house

GB - UNITED KINGDOM

Number of pages

19

Pages from-to

107447

UT code for WoS article

000509737600009

EID of the result in the Scopus database

2-s2.0-85075856144